Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: Correlation with clinico-pathological parameters and prognosis

International Journal of Medical Sciences

Volumn 10, Issue 2, 2012, Pages 133-140

  Im, Soyoung ^a   Yoo, Changyoung ^a   Jung, Ji Han ^a   Choi, Hyun Joo ^a   Yoo, Jinyoung ^a   Kang, Chang Suk ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Gastric cancer; TFF1; TFF3

Indexed keywords

TREFOIL FACTOR FAMILY 1; TREFOIL FACTOR FAMILY 3; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER;

GASTRIC CANCER; TFF1; TFF3;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84872159829     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5500     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-30.
3. Wright NA, Poulsom R, Stamp G, Van Noorden S, Sarraf C, Elia G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology. 1993; 104: 12-20.
4. May FE, Westley BR. Trefoil proteins: their role in normal and malignant cells. J Pathol. 1997; 183: 4-7.
5. Podolsky DK, Lynch-Devaney K, Stow JL, Oates P, Murgue B, DeBeaumont M, et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem. 1993; 268: 6694-702.
6. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W, Stamp GW. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 1997; 183: 30-8.
7. Devine DA, High AS, Owen PJ, Poulsom R, Bonass WA. Trefoil factor expression in normal and diseased human salivary glands. Hum Pathol. 2000; 31: 509-15.
8. Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W. Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J. 2000; 14: 1126-31.
9. dos Santos Silva E, Ulrich M, Doring G, Botzenhart K, Gott P. Trefoil factor family domain peptides in the human respiratory tract. J Pathol. 2000; 190: 133-42.
10. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003; 4: 721-32.
11. Hernandez C, Santamatilde E, McCreath KJ, Cervera AM, Diez I, Ortiz-Masia D, et al. Induction of trefoil factor (TFF)1, TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor-1: implications for gastric mucosal healing. Br J Pharmacol. 2009; 156: 262-72.
12. Henry JA, Bennett MK, Piggott NH, Levett DL, May FE, Westley BR. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer. 1991; 64: 677-82.
13. Chan VY, Chan MW, Leung WK, Leung PS, Sung JJ, Chan FK. Intestinal trefoil factor promotes invasion in non-tumorigenic Rat-2 fibroblast cell. Regul Pept. 2005; 127: 87-94.
14. Yio X, Zhang JY, Babyatsky M, Chen A, Lin J, Fan QX, et al. Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells. Clin Exp Metastasis. 2005; 22: 157-65.
15. Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 2005; 11: 6472-8.
16. Babyatsky M, Lin J, Yio X, Chen A, Zhang JY, Zheng Y, et al. Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis. 2009; 26: 143-51.
17. Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, et al. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A. 1998; 95: 3122-7.
18. Taupin D, Ooi K, Yeomans N, Giraud A. Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest. 1996; 75: 25-32.
19. Kirikoshi H, Katoh M. Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol. 2002; 21: 655-9.
20. Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 2002; 197: 582-8.
21. Vestergaard EM, Borre M, Poulsen SS, Nexo E, Torring N. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 2006; 12: 807-12.
22. Kaise M, Miwa J, Tashiro J, Ohmoto Y, Morimoto S, Kato M, et al. The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk. J Gastroenterol. 2011; 46: 736-45.
23. Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011; 141: 837-45.
24. Qu Y, Yang Y, Ma D, Xiao W. Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep. 2012; 27: 1277-83.
25. Yamachika T, Werther JL, Bodian C, Babyatsky M, Tatematsu M, Yamamura Y, et al. Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res. 2002; 8: 1092-9.
26. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17: 3077-9.
27. Meng JR, Tang HZ, Zhou KZ, Shen WH, Guo HY. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med. 2012.
28. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982; 10: 7895-903.
29. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer. 1991; 63: 615-22.
30. Kosriwong K, Menheniott TR, Giraud AS, Jearanaikoon P, Sripa B, Limpaiboon T. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. World J Gastroenterol. 2011; 17: 1631-41.
31. Weise A, Dunker N. High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low growth kinetics, increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of CDK6. Histochem Cell Biol. 2012.
32. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996; 274: 259-62.
33. Muller W, Borchard F. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival. J Pathol. 1993; 171: 263-9.
34. Machado JC, Carneiro F, Ribeiro P, Blin N, Sobrinho-Simoes M. pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study. Eur J Cancer. 1996; 32A: 1585-90.
35. Luqmani Y, Bennett C, Paterson I, Corbishley CM, Rio MC, Chambon P, et al. Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer. 1989; 44: 806-12.
36. Wu MS, Shun CT, Wang HP, Lee WJ, Wang TH, Lin JT. Loss of pS2 protein expression is an early event of intestinal-type gastric cancer. Jpn J Cancer Res. 1998; 89: 278-82.
37. Fiocca R, Villani L, Tenti P, Solcia E, Cornaggia M, Frigerio B, et al. Characterization of four main cell types in gastric cancer: foveolar, mucopeptic, intestinal columnar and goblet cells. An histopathologic, histochemical and ultrastructural study of early and advanced tumours. Pathol Res Pract. 1987; 182: 308-25.
38. Yoshikawa A, Inada Ki K, Yamachika T, Shimizu N, Kaminishi M, Tatematsu M. Phenotypic shift in human differentiated gastric cancers from gastric to intestinal epithelial cell type during disease progression. Gastric Cancer. 1998; 1: 134-41.
39. Fiocca R, Cornaggia M, Villani L, Capella C, Solcia E, Samloff IM. Expression of pepsinogen II in gastric cancer. Its relationship to local invasion and lymph node metastases. Cancer. 1988; 61: 956-62.
40. Suarez C, Vizoso F, Rodriguez JC, Garcia I, Raigoso P, Allende MT, et al. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int J Biol Markers. 2001; 16: 37-44.
41. Chan MW, Chan VY, Leung WK, Chan KK, To KF, Sung JJ, et al. Anti-sense trefoil factor family-3 (intestinal trefoil factor) inhibits cell growth and induces chemosensitivity to adriamycin in human gastric cancer cells. Life Sci. 2005; 76: 2581-92.
42. Taupin DR, Kinoshita K, Podolsky DK. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A. 2000; 97: 799-804.
43. Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, et al. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J. 2003; 17: 7-16.
44. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer. 1998; 1: 10-24.